Jalali R, Loughrey C, Baumert B, Perks J, Warrington A P, Traish D, Ashley S, Brada M
Neuro-Oncology Unit, The Institute of Cancer Research, The Royal Marsden NHS Trust, London, UK.
Clin Oncol (R Coll Radiol). 2002 Apr;14(2):103-9. doi: 10.1053/clon.2001.0040.
To present early clinical results of stereotactic conformal radiotherapy (SCRT) in patients with benign predominantly skull base meningiomas.
Between August 1994 and August 1999, 41 patients with benign residual or recurrent meningiomas were treated with SCRT. Thirty-three were histologically verified. All patients were immobilized in a GTC stereotactic relocatable frame, and underwent a post-contrast CT localization scan with additional MRI for fusion in 15 patients. Treatment was delivered on a 6 MV linear accelerator using three (12 patients), or 4 (29 patients) non-coplanar conformal fixed fields to doses of 50-55 Gy in 30-33 daily fractions. Tumours were relatively large with a median gross tumour volume (GTV) of 17.9 cm3 (range 2.5-183 cm3).
At a median follow-up of 21 months (range 6-62 months) none of 41 patients have recurred. The current imaging tumour control rate is 100% at 1 and 3 years. The actuarial survival at 2 years is 100% and 91% at 3 and 5 years. Following SCRT tumour decreased in size in 9 patients. SCRT was well tolerated. Five patients had improvement in vision, and six patients improvement in cranial nerve function. Two patients whose planning target volume (PTV) included the sella developed hypopituitarism during and at 18 months after SCRT. One patient with pre-existing hydrocephalus due to pineal region meningioma developed cognitive impairment 7 months after treatment. One patient with involvement of the optic nerve had visual deterioration at 18 months.
SCRT is a feasible high precision irradiation technique for residual and recurrent skull base meningiomas including both small and larger tumours with excellent early tumour control and low toxicity. Longer follow-up is necessary to demonstrate sustained tumour control and low morbidity of such high precision localized method of fractionated irradiation.
介绍立体定向适形放疗(SCRT)治疗以颅底为主的良性脑膜瘤患者的早期临床结果。
1994年8月至1999年8月,41例良性残留或复发性脑膜瘤患者接受了SCRT治疗。33例经组织学证实。所有患者均固定于GTC立体定向可重复定位框架中,15例患者在增强CT定位扫描后加做MRI用于融合。使用6 MV直线加速器,采用3个(12例患者)或4个(29例患者)非共面适形固定野进行治疗,剂量为50 - 55 Gy,分30 - 33次每日照射。肿瘤相对较大,中位肿瘤总体积(GTV)为17.9 cm³(范围2.5 - 183 cm³)。
中位随访21个月(范围6 - 62个月),41例患者均未复发。1年和3年时目前的影像学肿瘤控制率为100%。2年时精算生存率为100%,3年和5年时分别为91%。SCRT治疗后9例患者肿瘤体积缩小。SCRT耐受性良好。5例患者视力改善,6例患者脑神经功能改善。2例计划靶体积(PTV)包括蝶鞍的患者在SCRT治疗期间及治疗后18个月出现垂体功能减退。1例因松果体区脑膜瘤导致脑积水的患者在治疗后7个月出现认知障碍。1例视神经受累患者在18个月时视力恶化。
SCRT是一种可行的高精度放疗技术,适用于残留和复发性颅底脑膜瘤,包括大小不等的肿瘤,具有良好的早期肿瘤控制和低毒性。需要更长时间的随访来证明这种高精度局部分割照射方法的持续肿瘤控制和低发病率。